论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Tofacitinib 治疗 IL-17 抑制剂引起的银屑病样皮炎:一病例报告
Authors Luo N , Zhong L, Luo N , Wang Q , Li T, Hao P
Received 19 March 2023
Accepted for publication 10 May 2023
Published 19 May 2023 Volume 2023:16 Pages 2167—2172
DOI https://doi.org/10.2147/JIR.S412418
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Tara Strutt
Abstract: Psoriasis is a recurring systemic disease that can be treated with biologics to some effect. However, precisely targeting inflammatory mediators may disrupt immune system homeostasis and lead to new conditions. Here, we report a case of psoriasiform dermatitis (PsoD) caused by IL-17 inhibitors (IL-17i) namely secukinumab treatment for psoriasis. This case proposes an effective use of Janus kinase inhibitor (JAKi) tofacitinib to confront lesions induced by IL-17i. This is the first case report of PsoD caused by secukinumab treated with tofacitinib.
Keywords: tofacitinib, Janus kinase inhibitor, psoriasiform dermatitis, Th1-Th2 balance, IL-17 inhibitors